There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Thrombolytic therapy for acute ischemic stroke has been approached cautiously because
there were high rates of intracerebral hemorrhage in early clinical trials. We performed
a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator
(t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial
when treatment was begun within three hours of the onset of stroke.